Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

Patient sample and mouse studies suggest inhibiting MMP9 could help treat DME. Levels of MMP9 and a truncated form of the MMP9 substrate NTN1 were higher in vitreous humor samples from DME patients than in samples from healthy volunteers. In a mouse model of DME, a MMP9 inhibitor tool compound decreased retinal permeability - a marker of DME disease progression - compared with vehicle. Next steps could include identifying and testing small molecule MMP9 inhibitors in large animal models of DME.

Gilead Sciences Inc. has GS-5745, an MMP9 mAb inhibitor, in Phase III testing to treat gastric cancer, Phase II/III testing to treat inflammatory bowel disease (IBD), Phase II testing to treat Crohn's disease and Phase I testing to treat chronic obstructive pulmonary disease (COPD), rheumatoid arthritis and solid tumors. ...